Virus dynamics and drug therapy
نویسندگان
چکیده
منابع مشابه
Virus dynamics and drug therapy.
The recent development of potent antiviral drugs not only has raised hopes for effective treatment of infections with HIV or the hepatitis B virus, but also has led to important quantitative insights into viral dynamics in vivo. Interpretation of the experimental data depends upon mathematical models that describe the nonlinear interaction between virus and host cell populations. Here we discus...
متن کاملHuman immunodeficiency virus drug therapy and virus load.
Analysis of the short-term dynamics of human immunodeficiency virus (HIV) type 1 infection in response to drug therapy has elucidated crucial kinetic properties of viral dynamics in vivo (D. D. Ho et al., Nature 373:123-126, 1995; A. S. Perelson et al., Science 271:1582-1586, 1996; X. Wei et al., Nature 373:117-122, 1995). Here we investigated long-term changes in virus load in patients treated...
متن کاملModeling the dynamics of hepatitis C virus with combined antiviral drug therapy: interferon and ribavirin.
A mathematical modeling of hepatitis C virus (HCV) dynamics and antiviral therapy has been presented in this paper. The proposed model, which involves four coupled ordinary differential equations, describes the interaction of target cells (hepatocytes), infected cells, infectious virions and non-infectious virions. The model takes into consideration the addition of ribavirin to interferon thera...
متن کاملTruncated Hepatitis B virus like nanoparticles: A novel drug delivery platform for cancer therapy
Nowadays, Nano-sized drug delivery systems have been studied extensively for theirpotential in cancer therapy. Various drug nanocarriers are being developed including liposomes, micelles, and Virus like nanoparticles (VLNPs). VLNPs offer many advantages for developing smart drug delivery systems due to their precise and repeated structures and relatively large cargo capacities. Truncated ...
متن کاملHepatitis B Virus Drug Resistance and Combination Therapy
Despite the development of new nucleoside analogs, antiviral therapy of chronic hepatitis B remains a major clinical challenge. Indeed, because of both viral genome persistence and hepatitis B virus genome heterogeneity, these antivirals may select for drug-resistant mutants. The development of drug resistance is associated with liver disease progression. The progress made in virologic assays a...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Proceedings of the National Academy of Sciences
سال: 1997
ISSN: 0027-8424,1091-6490
DOI: 10.1073/pnas.94.13.6971